Fibroblast growth factor 21 in chronic kidney disease

Anuwatmatee, Sahapab; Tang, Shoufeng; Wu, Ben J.; Rye, Kerry‐Anne

doi:10.1016/j.cca.2017.11.002

Cited by 32 publications

(39 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to the healthy population, the FGF21 levels were elevated 10 to 20 fold in ESRD patients. Beyond the renal clearance, accumulation of FGF21 may contribute by insulin resistance, chronic inflammation, and increased oxidative stress in uremic circumstances [31,32]. However, our study did not measure insulin resistance, inflammation, and oxidative stress.…”

Section: Discussionmentioning

confidence: 85%

Lower Serum Fibroblast Growth Factor 21 Levels are Associated with Normal Lumbar Spine Bone Mineral Density in Hemodialysis Patients

Hsu

Wang

et al. 2020

IJERPH

View full text Add to dashboard Cite

Recent evidence has indicated that fibroblast growth factor 21 (FGF21) regulates longitudinal bone growth, with increased FGF21 levels leading to bone loss. The present study evaluated the relationship between bone mineral density (BMD) and serum FGF21 levels in patients undergoing hemodialysis (HD). We analyzed blood samples from 95 patients undergoing HD and measured BMD using dual-energy X-ray absorptiometry of the lumbar vertebrae (L2–L4). Serum FGF21 concentrations were determined using a commercially available enzyme-linked immunosorbent assay kit. Thirteen (11.6%) patients were found to have osteoporosis, 27 (28.4%) osteopenia, and 57 patients had normal BMD. Advanced age and decreased body mass index, height, body weight, waist circumference, and triglyceride level were associated with lower lumbar T-scores, as were increased alkaline phosphatase, urea reduction rate, fractional clearance index for urea, and FGF21 levels. Low log-FGF21, increased body mass index, increased pre-HD body weight, and increased logarithmically transformed triglycerides (log-TG) were found to be significantly and independently associated with lumbar BMD by multivariate forward stepwise linear regression analysis with adjustment for significant confounders. We conclude that high serum FGF21 level is negatively associated with BMD in patients undergoing HD.

show abstract

Section: Discussionmentioning

confidence: 85%

Lower Serum Fibroblast Growth Factor 21 Levels are Associated with Normal Lumbar Spine Bone Mineral Density in Hemodialysis Patients

Hsu

Wang

et al. 2020

IJERPH

View full text Add to dashboard Cite

show abstract

“…Fibroblast growth factor 21 (FGF21) is a metabolic hormone that is expressed mainly in the liver to maintain homeostasis [ 1 ]. High level of circulating FGF21 is known to be induced by many metabolic disorders, such as type 2 diabetes, obesity, chronic kidney disease, non-alcoholic fatty liver disease, and cardiovascular diseases [ 2 3 4 5 ]. Recently, Markan et al [ 6 ] demonstrated that the serum FGF21 is produced from the liver, and not from adipose tissue.…”

Section: Introductionmentioning

confidence: 99%

Association between Serum Fibroblast Growth Factor 21 Levels and Bone Mineral Density in Postmenopausal Women

et al. 2018

View full text Add to dashboard Cite

BackgroundDespite the beneficial effect of fibroblast growth factor 21 (FGF21) on metabolic disease, there are concerns about adverse effects on bone metabolism, supported by animal studies. However, a recent human study showed the positive association between serum FGF21 level and bone mineral density (BMD) in healthy premenopausal women. We undertook this study to examine the association between FGF21 level and BMD in healthy postmenopausal Korean women who are susceptible to osteoporosis.MethodsWe used data of 115 participants from a cohort of healthy postmenopausal women (>50 years old) to examine the association between serum FGF21 level and BMD. The clinical characteristics were obtained from the participants, and blood testing and serum FGF21 testing were undertaken. BMD of the lumbar spine, femoral neck and total hip area, and bone markers were used in the analyses.ResultsThe mean age of the participants was 60.2±7.2 years. Serum FGF21 levels showed negative correlation with BMD and T-scores in all three areas, but there were no statistically significant differences. Multivariate analyses with adjustment for age and body mass index also did not show significant association between serum FGF21 level and BMD. In addition, serum FGF21 level also showed no correlation with osteocalcin and C-telopeptide levels.ConclusionIn our study, serum FGF21 level showed no significant correlation with BMD and T-scores.

show abstract

“…[39] Many studies have indicated that serum FGF21 levels were negatively correlated with renal function and were elevated 8-15 folds in patients receiving dialysis in comparison to controls. [19,20] In our study, the median serum FGF21 level in HD patients was elevated 11-fold compared with healthy controls (Table 6). Serum FGF21 levels were positively correlated with TACS in our HD patients, which suggested serum FGF21 increased with the extent of TAC in HD patients.…”

Section: Discussionmentioning

confidence: 48%

“…FGF21 is also increased progressively with a decline of renal function. [19,20] Circulating FGF21 is mainly secreted from the liver as a metabolic regulator of glucose metabolism and lipid metabolism in response to fasting. [21] In obese rodents, it causes weight loss [22] and improves insulin sensitivity [23,24].…”

Section: Introductionmentioning

confidence: 99%

Fibroblast Growth Factor 21 Predicts and Promotes Vascular Calcification in Haemodialysis Patients

Jiang

Yin

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Cardiovascular disease (CVD) is the leading cause of death in haemodialysis (HD) patients. Vascular calcification (VC) is dramatically accelerated and is strongly associated with CVD events and mortality in HD patients. VC coexists with osteoporosis in many studies. Fibroblast growth factor 21 (FGF21) as an adipocytokines is a new hypoglycemic strategy and is inversely related to bone mineral density.Methods: To evaluate the contribution of FGF21 to VC in HD patients, we preliminary sreened 802 HD patients of two large HD centers in China. At last 388 HD patients were entered this cross-sectional study. We detected circulating FGF21 levels and measured the whole thoracic aorta calcification scores (TACS) and calcification scores of the three segments of thoracic aorta (TA), including ascending thoracic aorta (ATACS), aortic arch (AoACS), and descending thoracic aorta (DTACS) of our 388 HD patients. In addition, we pre-incubated human aortic endothelial cells (HAECs) with FGF21 in the presence or absence of parathyroid hormone (PTH) in vitro.Results: The median serum FGF21 level in HD patients was 11-fold higher than that in healthy controls. Ln(FGF21) was positively correlated with Ln(TACS+1), Ln(ATACS+1), Ln(AoACS+1) and Ln(DTACS+1) respectively in HD patients. Serum FGF21 was independently associated with TACS and ATACS, AoACS, and DTACS. FGF21 combined with age, calcium and intact parathyroid hormone demonstrated a high area under the curve (AUC=0.84) with optimal sensitivity (84%) and specificity (71%) for the prediction of VC in HD patients. Our vitro results showed that FGF21 enhanced the calcification effect of PTH on HAECs by increasing calcium deposition and endothelial-to-mesenchymal transition (EndMT).Conclusions: Circulating FGF21 was notably higher and was a potential predictor and promoter of VC in HD patients.Trial registration Chinese Clinical Trial Registry, identifier: ChiCTR1900028249. Registered 16 December 2019-Retrospectively registered,http://www.medresman.org.cn/uc/project/projectedit.aspx?proj=5981

show abstract

Fibroblast growth factor 21 in chronic kidney disease

Cited by 32 publications

References 70 publications

Lower Serum Fibroblast Growth Factor 21 Levels are Associated with Normal Lumbar Spine Bone Mineral Density in Hemodialysis Patients

Lower Serum Fibroblast Growth Factor 21 Levels are Associated with Normal Lumbar Spine Bone Mineral Density in Hemodialysis Patients

Association between Serum Fibroblast Growth Factor 21 Levels and Bone Mineral Density in Postmenopausal Women

Fibroblast Growth Factor 21 Predicts and Promotes Vascular Calcification in Haemodialysis Patients

Contact Info

Product

Resources

About